

Press release

Lund, September 8, 2021
EQL Pharma AB (publ)
556713-3425

EQL PHARMA

Ondansetron EQL Pharma Approved

The pharmaceutical Ondansetron EQL Pharma tablets 4mg and 8mg have been approved by the Swedish Medical Products Agency for sale in Sweden. Approval is also expected soon for Denmark.

Ondansetron EQL Pharma is by prescription only and is used in the treatment of nausea and vomiting in connection with radiation therapy or chemotherapy. It is also used in prevention of nausea and vomiting in connection with surgical operations.

Ondansetron EQL Pharma has a launch date in the company's first financial quarter next year. The markets in Sweden and Denmark currently have sales of approximately SEK 15m and have between three and six active competitors per market.

For further information, please contact:

Christer Fåhraeus

CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00

E-mail: christer.fahraeus@eqlpharma.com

Website: www.eqlpharma.com

EQL Pharma AB specializes in developing and selling generics, ie pharmaceuticals that are medically equivalent to reference pharmaceuticals. The company currently has upwards of 20 niche generics (ie generics with limited competition apart from the reference pharmaceutical) approved in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2021 and beyond. The business is currently entirely focused on prescription pharmaceuticals, including hospital products, in the Nordic region and in selected European markets. EQL Pharma AB conducts its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and pharmaceutical companies in the EU and Asia, among others.